APOE ε4 moderates amyloid-related memory decline in preclinical Alzheimer's disease
APOE ε4 moderates amyloid-related memory decline in preclinical Alzheimer's disease
复制标题
DOI：
10.1016/j.neurobiolaging.2014.12.008
复制
发表时间：
2015-03-01
影响因子：
4.2
通讯作者：
Maruff, Paul
中科院分区：
文献类型：
--
作者：
Lim, Yen Ying;Villemagne, Victor L.;Maruff, Paul
载脂蛋白E（APOE）β 4等位基因和高水平的β-淀粉样蛋白（A β）与情景记忆衰退和阿尔茨海默病风险相关。然而，关于β 4对健康老年人A β相关记忆衰退的独立或交互作用存在争议。本研究纳入了入组澳大利亚成像、生物标志物和生活方式研究的A β负荷高的健康老年人（n = 84）。在基线、18个月、36个月和54个月随访时，使用计算机化认知状态简易成套测验测量认知。在基线和每个随访时间点还进行了简易精神状态检查和临床痴呆评定量表。相对于A β + β 4非携带者（n = 36），A β + β 4携带者（n = 48）在记忆任务上表现出明显更快的下降，按照惯例，其幅度为中度（d = 0.40-0.47）。在54个月的评估期内，与APOE β 4相关的β阳性与记忆力下降中度增加相关，这表明在阿尔茨海默病的临床前阶段，具有高A β的老年人的记忆力下降的表现因APOE β 4的存在而加剧。(C)2015 Elsevier Inc. All rights reserved.
The apolipoprotein E (APOE) epsilon 4 allele and high levels of beta-amyloid (A beta) are associated with episodic memory decline and risk for Alzheimer's disease. However, there is debate about independent or interactive effects of epsilon 4 on A beta-related memory decline in healthy older adults. Healthy older adults with high A beta burden (n = 84) enrolled in Australian Imaging, Biomarkers, and Lifestyle Study were included in this study. Cognition was measured using the computerized Cogstate Brief Battery at baseline, 18-, 36-, and 54-month follow-ups. Mini Mental State Examination and Clinical Dementia Rating scales were also administered at baseline and each follow-up timepoint. Relative to A beta + epsilon 4 noncarriers (n - 36), A beta + epsilon 4 carriers (n = 48) showed significantly faster decline on memory tasks, which was by convention, moderate in magnitude (d = 0.40-0.47). A beta positivity coupled with APOE epsilon 4 was associated with moderately increased decline in memory over a 54-month assessment period, suggesting that, in the preclinical stages of Alzheimer's disease, the manifestation of memory decline in older adults with high A beta is exacerbated by the presence of APOE epsilon 4. (C) 2015 Elsevier Inc. All rights reserved.